{
    "organizations": [],
    "uuid": "02105349d15318df14cccd67949a96ffcefa169c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-immunomedics-submits-biologics-lic/brief-immunomedics-submits-biologics-license-application-for-sacituzumab-govitecan-to-the-u-s-fda-idUSASC0A30X",
    "ord_in_thread": 0,
    "title": "BRIEF-Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. FDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21 (Reuters) - Immunomedics Inc:\n* IMMUNOMEDICS SUBMITS BIOLOGICS LICENSE APPLICATION FOR SACITUZUMAB GOVITECAN TO THE U.S. FOOD AND DRUG ADMINISTRATION\n* IMMUNOMEDICS INC - FILING IS BASED ON PHASE 1/2 DATA OF SACITUZUMAB GOVITECAN IN MTNBC Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-21T20:18:00.000+03:00",
    "crawled": "2018-05-22T19:36:34.021+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "immunomedics",
        "inc",
        "immunomedics",
        "submits",
        "biologics",
        "license",
        "application",
        "sacituzumab",
        "govitecan",
        "food",
        "drug",
        "administration",
        "immunomedics",
        "inc",
        "filing",
        "based",
        "phase",
        "data",
        "sacituzumab",
        "govitecan",
        "mtnbc",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}